Stock listing
OTC:AMBBY Ambu A/S Stock
US listing (OTC) of Ambu A/S · home listing Copenhagen:AMBUB
Follow Ambu A/S into a list and get an email when it puts out news.
Share price · OTC:AMBBY
$12.53 USD -0.77 (-5.8%)
Close on Nov 20, 2026
- Day range
- $12.53 – $12.53 USDNov 20, 2026
- Volume
- 8 sharesNov 20, 2026
- Market cap
- $3.27B USDAt the close on Nov 20, 2026 · price × 260.7M shares outstanding
- 52-week range
- $8.55 – $14.18 USDLowest and highest trades, Nov 25, 2025 – Nov 20, 2026
- Traded on an average day
- $1,374 USDMedian day 0 shares · 33 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| OTC:AMBFF | $12.57 USD | +0.57 (+4.8%) | 160 | $12.57 | $12.57 | $12.57 | $12.00 | Close on Nov 12, 2026 |
| OTC:AMBBY | $12.53 USD | -0.77 (-5.8%) | 8 | $12.53 | $12.53 | $12.53 | $13.30 | Close on Nov 20, 2026 |
| Frankfurt:547A | €11.54 EUR | -0.31 (-2.6%) | — | €11.57 | €11.57 | €11.54 | €11.85 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · OTC:AMBBY · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $13.00 | -0.60 | -4.4% | $13.00 | $13.00 | $13.00 | 500 | |
| $13.60 | +0.40 | +3.0% | $13.60 | $13.60 | $13.60 | 1,000 | |
| $13.20 | +1.10 | +9.1% | $13.20 | $13.20 | $13.20 | 100 | |
| $12.10 | +0.46 | +4.0% | $12.10 | $12.10 | $12.10 | 500 | |
| $11.64 | 0.00 | 0.0% | $11.64 | $11.64 | $11.64 | 0 | |
| $11.64 | 0.00 | 0.0% | $11.64 | $11.64 | $11.64 | 0 | |
| $11.64 | 0.00 | 0.0% | $11.64 | $11.64 | $11.64 | 0 | |
| $11.64 | 0.00 | 0.0% | $11.64 | $11.64 | $11.64 | 0 | |
| $11.64 | 0.00 | 0.0% | $11.64 | $11.64 | $11.64 | 0 | |
| $11.64 | 0.00 | 0.0% | $11.64 | $11.64 | $11.64 | 0 | |
| $11.64 | 0.00 | 0.0% | $11.64 | $11.64 | $11.64 | 0 | |
| $11.64 | 0.00 | 0.0% | $11.64 | $11.64 | $11.64 | 0 | |
| $11.64 | 0.00 | 0.0% | $11.64 | $11.64 | $11.64 | 60 | |
| $11.64 | 0.00 | 0.0% | $11.64 | $11.64 | $11.64 | 0 | |
| $11.64 | 0.00 | 0.0% | $11.64 | $11.64 | $11.64 | 68 | |
| $11.64 | 0.00 | 0.0% | $11.64 | $11.64 | $11.64 | 0 | |
| $11.64 | 0.00 | 0.0% | $11.64 | $11.64 | $11.64 | 0 | |
| $11.64 | +0.64 | +5.8% | $11.64 | $11.64 | $11.64 | 100 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 2 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 1 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 1 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | +0.775 | +7.6% | $11.00 | $11.00 | $11.00 | 200 | |
| $10.23 | 0.00 | 0.0% | $10.23 | $10.23 | $10.23 | 0 | |
| $10.23 | 0.00 | 0.0% | $10.23 | $10.23 | $10.23 | 2 | |
| $10.23 | -0.025 | -0.2% | $10.23 | $10.23 | $10.23 | 1,000 | |
| $10.25 | 0.00 | 0.0% | $10.25 | $10.25 | $10.25 | 0 | |
| $10.25 | 0.00 | 0.0% | $10.25 | $10.25 | $10.25 | 0 | |
| $10.25 | 0.00 | 0.0% | $10.25 | $10.25 | $10.25 | 254 | |
| $10.25 | 0.00 | 0.0% | $10.25 | $10.25 | $10.25 | 0 | |
| $10.25 | 0.00 | 0.0% | $10.25 | $10.25 | $10.25 | 0 | |
| $10.25 | 0.00 | 0.0% | $10.25 | $10.25 | $10.25 | 254 | |
| $10.25 | +0.055 | +0.5% | $10.25 | $10.25 | $10.25 | 300 | |
| $10.20 | 0.00 | 0.0% | $10.20 | $10.20 | $10.20 | 7 | |
| $10.20 | -0.805 | -7.3% | $10.20 | $10.20 | $10.20 | 300 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 19 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 60 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | 0.00 | 0.0% | $11.00 | $11.00 | $11.00 | 0 | |
| $11.00 | +0.49 | +4.7% | $11.00 | $11.00 | $11.00 | 1,000 | |
| $10.51 | 0.00 | 0.0% | $10.51 | $10.51 | $10.51 | 53 | |
| $10.51 | -1.14 | -9.8% | $10.51 | $10.51 | $10.51 | 1,000 | |
| $11.65 | 0.00 | 0.0% | $11.65 | $11.65 | $11.65 | 0 | |
| $11.65 | 0.00 | 0.0% | $11.65 | $11.65 | $11.65 | 0 | |
| $11.65 | 0.00 | 0.0% | $11.65 | $11.65 | $11.65 | 0 | |
| $11.65 | 0.00 | 0.0% | $11.65 | $11.65 | $11.65 | 0 |
- Ticker
- OTC:AMBBY
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · May 6, 2026
AMBU_B: Endoscopy Solutions growth offsets A&PM headwinds; guidance narrowed, share buyback expanded
Latest earnings call · Aug 26, 2026
Ambu (Copenhagen:AMBU B) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Aug 26, 2026
Ambu A S Ord — Q3 2026 Earnings Presentation
Earnings · 37 slides
Latest news
AMBU_B: Endoscopy Solutions growth offsets A&PM headwinds; guidance narrowed, share buyback expanded
May 6, 2026
Closed $9.98 (-6.3%) on May 6, 2026
Ambu Share Buyback Program Ends
Feb 12, 2026
Closed $12.94 (0.0%) on Feb 12, 2026
AMBU_B: Strong Q1 growth in endoscopy and urology, with EBIT margin on track despite tariff and FX headwinds
Feb 4, 2026
Closed $13.82 (+4.7%) on Feb 4, 2026
AMBU_B: Double-digit growth and innovation drive global endoscopy leadership ambitions
Jan 14, 2026
Closed $13.80 (0.0%) on Jan 14, 2026
Ambu A/S on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 4 in the last 12 months · 20 in all · newest May 6, 2026 · oldest 2024
- Calls
- 21 calls with a replay · 21 with a transcript · latest Aug 26, 2026
- Decks
- 74 decks · latest Aug 26, 2026
Where Ambu A/S is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Copenhagen:AMBUB · Home listing | Copenhagen | Denmark | DKK |
| Aquis:AMBUBC | Aquis | United Kingdom | DKK |
| VIE:AMBU | Vienna | Austria | EUR |
| gettex:547A | gettex | Germany | EUR |
| OTC:AMBFF | OTC | United States | USD |
| LSIN:0MJF | LSIN | United Kingdom | DKK |
| Aquis:AMBUBC | Aquis | United Kingdom | DKK |
| OTC:AMBBY · This page | OTC | United States | USD |
| Tradegate:547A | Tradegate | Germany | EUR |
| LS Exchange:A2JAHY | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2JAHY | Lang & Schwarz | Germany | EUR |
| Frankfurt:547A | Frankfurt | Germany | EUR |
| Munich:547A | Munich | Germany | EUR |
| Turquoise:AMBUBC | Turquoise | United Kingdom | DKK |
| Dusseldorf:547A | Dusseldorf | Germany | EUR |
| Hamburg:547A | Hamburg | Germany | EUR |
| Hanover:547A | Hanover | Germany | EUR |
| Stuttgart:547A | Stuttgart | Germany | EUR |
Valuation
P/E 30.9× against a median of 29.1×: 4th lowest of 7 Medical devices & supplies companies shown. Statements: Year to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- 19.93B DKK
- P/E
- 30.9×
- EV/sales
- 3.1×
- EV/EBITDA
- 15.9×
- Price/book
- 3.2×
- Gross margin
- 60.1%
- Operating margin
- 13.2%
- Net margin
- 9.9%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Ambu A/S Class B · OMXCOP:AMBU_B | US$2.92B | US$2.92B | 30.9× | 3.1× | 15.9× | 3.2× | 9.9% | 0.1× | n/a |
| Pulse Biosciences, Inc · NASDAQ:PLSE | US$3.35B | US$3.17B | n/a | 2,120× | n/a | 18.3× | n/a | 0.0× | 1.54 |
| Axogen, Inc. · NASDAQ:AXGN | US$3.33B | US$2.98B | n/a | 11.2× | n/a | 6.7× | −12.0% | 0.0× | 0.98 |
| Zhende Medical Co., Ltd. Class A · SSE:603301 | US$3.23B | US$3.13B | 73.1× | 4.5× | n/a | 3.8× | 6.3% | 0.1× | n/a |
| Lepu Medical Technology (Beijing) Co., Ltd. Class A · SZSE:300003 | US$3.10B | US$3.03B | 31.4× | 3.3× | n/a | 1.3× | 10.7% | 0.2× | n/a |
| Carl Zeiss Meditec AG · XETR:AFX | US$3.06B | US$3.06B | 23.9× | 1.1× | n/a | 1.3× | 4.4% | 0.0× | n/a |
| Imricor Medical Systems, Inc. · ASX:IMR | US$2.99B | US$2.96B | n/a | 9,790× | n/a | 103× | n/a | 1.2× | n/a |
| TransMedics Group, Inc. · NASDAQ:TMDX | US$2.96B | US$2.52B | 20.5× | 3.5× | 19.8× | 5.4× | 19.9% | 0.1× | 1.31 |
| AtriCure, Inc. · NASDAQ:ATRC | US$2.82B | US$2.69B | 190× | 4.6× | 75.2× | 5.3× | 2.5% | 0.1× | 0.58 |
| Shanghai MicroPort MedBot (Group) Co., Ltd. Class H · HKEX:2252 | US$2.77B | US$2.74B | n/a | 33.1× | n/a | 44.9× | −45.3% | 1.0× | n/a |
| Ottobock SE & Co. KGaA · XETR:OBCK | US$2.65B | US$3.54B | 26.8× | 1.9× | 8.0× | 6.1× | 5.4% | 2.3× | n/a |
| Median of the others | US$3.03B | US$3.01B | 29.1× | 4.5× | 19.8× | 5.7× | 4.9% | 0.1× | 1.15 |
Forecasts
Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 97.66 DKK · Analysts' mean
- EPS, year to Sep 2027
- 3.12 · 8 analysts
- Revenue, year to Sep 2027
- 7.32B · 8 analysts
Team and board
| Officer | Role |
|---|---|
| Britt Meelby Jensen | Chief Executive Officer |
| Henrik Skak Bender | Chief Financial Officer |
| Scott Heinzelman | President of Ambu North America |
| Finn Möhring | Chief Technology Officer, R&D |
| Graziela Malucelli | Chief Operations Officer |
| Jesper Johnsen Steen | Chief Marketing Officer |
Events
- Next results
- Jan 28, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Ambu (Copenhagen:AMBU B) Q3 2026 Earnings Call | Wed, Aug 26, 2026 · 5:00 AM ET | Replay |
| Ambu (Copenhagen:AMBU B) Q2 2026 Earnings Call | Wed, May 06, 2026 · 5:00 AM ET | Replay |
| Ambu (Copenhagen:AMBU B) Q1 2026 Earnings Call | Wed, Feb 04, 2026 · 5:00 AM ET | Replay |
| Ambu (Copenhagen:AMBU B) Q4 2025 Earnings Call | Wed, Nov 05, 2025 · 5:00 AM ET | Replay |
| Ambu (Copenhagen:AMBU B) Q3 2025 Earnings Call | Fri, Aug 22, 2025 · 4:00 AM ET | Replay |
| Ambu (Copenhagen:AMBU B) Q2 2025 Earnings Call | Wed, May 07, 2025 · 5:00 AM ET | Replay |
| Ambu (Copenhagen:AMBU B) Q1 2025 Earnings Call | Thu, Jan 30, 2025 · 5:00 AM ET | Replay |
| Ambu (Copenhagen:AMBU B) Q4 2024 Earnings Call | Tue, Nov 05, 2024 · 4:00 AM ET | Replay |
| Ambu (Copenhagen:AMBU B) Q3 2024 Earnings Call | Fri, Aug 30, 2024 · 5:00 AM ET | Replay |
| Ambu (Copenhagen:AMBU B) Q2 2024 Earnings Call | Tue, May 14, 2024 | Replay |
All 21 calls
| Call | When | Status |
|---|---|---|
| Ambu (Copenhagen:AMBU B) Q1 2024 Earnings Call | Tue, Jan 30, 2024 | Replay |
| Ambu (Copenhagen:AMBU B) Q4 2023 Earnings Call | Sun, Oct 08, 2023 | Replay |
| Ambu (Copenhagen:AMBU B) Q2 2023 Earnings Call | Mon, May 08, 2023 | Replay |
| Ambu (Copenhagen:AMBU B) Q1 2023 Earnings Call | Tue, Feb 07, 2023 | Replay |
| Ambu (Copenhagen:AMBU B) Q4 2022 Earnings Call | Tue, Nov 15, 2022 | Replay |
| Ambu (Copenhagen:AMBU B) Q3 2022 Earnings Call | Thu, Aug 25, 2022 | Replay |
| Ambu (Copenhagen:AMBU B) Q1 2022 Earnings Call | Tue, Feb 08, 2022 | Replay |
| Ambu (Copenhagen:AMBU B) Q4 2021 Earnings Call | Fri, Nov 12, 2021 | Replay |
| Ambu (Copenhagen:AMBU B) Q3 2021 Earnings Call | Tue, Aug 17, 2021 | Replay |
| Ambu (Copenhagen:AMBU B) Q4 2020 Earnings Call | Wed, Nov 11, 2020 | Replay |
| Ambu (Copenhagen:AMBU B) Q3 2020 Earnings Call | Wed, Aug 26, 2020 | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q4 2026 | Nov 5, 2026 · Before open | +4.2% |
| Q3 2026 | Aug 25, 2026 · After close | −15.8% |
| Q2 2026 | May 6, 2026 · Before open | −3.7% |
| Q1 2026 | Feb 4, 2026 · Before open | +5.6% |
| Q4 2025 | Nov 5, 2025 · Before open | −15.8% |
| Q3 2025 | Aug 22, 2025 · Before open | +6.6% |
| Q2 2025 | May 7, 2025 · Before open | −13.5% |
| Q1 2025 | Jan 30, 2025 · Before open | −1.3% |
| Q4 2024 | Nov 4, 2024 · After close | −8.7% |
| Q3 2024 | Aug 30, 2024 · Before open | −16.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2024 | May 14, 2024 · Before open | −0.8% |
| Q1 2024 | Jan 30, 2024 · Before open | +6.5% |
| Q4 2023 | Nov 8, 2023 · Before open | +8.9% |
| Q3 2023 | Aug 31, 2023 · Before open | −6.4% |
| Q2 2023 | May 3, 2023 · Before open | +2.9% |
| Q1 2023 | Feb 7, 2023 · Before open | +12.5% |
| Q4 2022 | Nov 15, 2022 · Before open | −14.8% |
| Q3 2022 | Aug 25, 2022 · Before open | +8.2% |
| Q2 2022 | May 5, 2022 · After close | −11.8% |
| Q1 2022 | Feb 8, 2022 · Before open | −6.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Ambu A S Ord — Q3 2026 Earnings Presentation | Earnings | 37 slides | Aug 26, 2026 |
| Ambu A S Ord — Q2 2026 Earnings Presentation | Earnings | 35 slides | May 6, 2026 |
| Ambu A S Ord — Q1 2026 Earnings Presentation | Earnings | 37 slides | Feb 4, 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 25 slides | January 2026 |
| Ambu A S Ord — FY 2024/25 Earnings Presentation | Earnings | 27 slides | Nov 5, 2025 |
| Investor Day (October 2025) | Investor day | 176 slides | Oct 1, 2025 |
| Ambu A S Ord — Q3 2025 Earnings Presentation | Earnings | 22 slides | Aug 22, 2025 |
| Ambu A S Ord — Q2 2025 Earnings Presentation | Earnings | 41 slides | May 7, 2025 |
| Ambu A S Ord — Q1 2025 Earnings Presentation | Earnings | 40 slides | Jan 30, 2025 |
| Ambu A S Ord — Q4 2024 Earnings Presentation | Earnings | 45 slides | Nov 5, 2024 |
Show 50 decks
This page holds 50 of 74 decks. Open Decks
Financials
Annual, in DKK
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.47B | 6.04B | 5.39B | 4.78B | 4.44B | 4.01B | 3.57B | 2.82B | 2.61B | 2.35B |
| Cost of revenue | 2.58B | 2.40B | 2.19B | 2.06B | 1.89B | 1.51B | 1.35B | 1.18B | 1.06B | 1.02B |
| Gross profit | 3.89B | 3.63B | 3.20B | 2.71B | 2.55B | 2.50B | 2.21B | 1.64B | 1.55B | 1.33B |
| Research and development | 369.0M | 347.0M | 325.0M | 295.0M | 281.0M | 225.0M | 157.0M | 103.0M | 111.0M | 76.0M |
| Selling, general and administrative | 780.0M | 660.0M | 594.0M | 517.0M | 470.0M | 399.0M | 292.0M | 266.0M | 256.0M | |
| Operating income | 851.0M | 784.0M | 311.0M | 302.0M | 144.0M | 340.0M | 428.0M | 499.0M | 563.0M | 450.0M |
| Depreciation and amortization | 401.0M | 372.0M | 364.0M | 330.0M | 301.0M | 216.0M | 181.0M | 109.0M | 115.0M | 105.0M |
| EBITDA | 1.25B | 1.16B | 675.0M | 632.0M | 445.0M | 556.0M | 609.0M | 608.0M | 678.0M | 555.0M |
| Interest expense | 25.0M | 44.0M | 27.0M | 61.0M | 32.0M | 26.0M | 28.0M | 20.0M | 31.0M | 33.0M |
| Income before tax | 840.0M | 755.0M | 300.0M | 210.0M | 109.0M | 308.0M | 322.0M | 413.0M | 465.0M | 393.0M |
| Income tax | 198.0M | 146.0M | 65.0M | 42.0M | 16.0M | 61.0M | 81.0M | 96.0M | 128.0M | 92.0M |
| Net income | 642.0M | 609.0M | 235.0M | 168.0M | 93.0M | 247.0M | 241.0M | 317.0M | 337.0M | 301.0M |
| Earnings per share, basic | 2.42 | 2.29 | 0.88 | 0.64 | 0.37 | 0.98 | 0.97 | 1.28 | 1.36 | 1.24 |
| Earnings per share, diluted | 2.28 | 0.88 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 536.0M | 866.0M | 615.0M | 157.0M | 187.0M | 64.0M | 98.0M | 120.0M | 63.0M | 19.0M |
| Receivables | 1.04B | 907.0M | 829.0M | 860.0M | 806.0M | 732.0M | 564.0M | 495.0M | 504.0M | 453.0M |
| Inventory | 1.36B | 1.27B | 1.08B | 907.0M | 1.22B | 748.0M | 515.0M | 506.0M | 382.0M | 313.0M |
| Current assets | 3.10B | 3.16B | 2.64B | 2.01B | 2.30B | 1.61B | 1.24B | 1.16B | 985.0M | 816.0M |
| Property, plant and equipment | 588.0M | 582.0M | 1.28B | 846.0M | 664.0M | 521.0M | 426.0M | 305.0M | ||
| Goodwill | 1.75B | 1.50B | 1.53B | 1.56B | 1.62B | 1.50B | 1.50B | 1.55B | 1.50B | 781.0M |
| Total assets | 8.22B | 7.67B | 7.15B | 6.86B | 7.21B | 5.74B | 4.93B | 4.56B | 4.23B | 2.50B |
| Accounts payable | 615.0M | 572.0M | 490.0M | 359.0M | 600.0M | 364.0M | 259.0M | 266.0M | 194.0M | 160.0M |
| Current liabilities | 1.32B | 1.16B | 1.06B | 942.0M | 1.16B | 980.0M | 1.04B | 1.01B | 474.0M | 1.10B |
| Long-term debt | 33.0M | 0 | 1.25B | 550.0M | 1.25B | 1.05B | 1.20B | |||
| Total debt | 593.0M | 547.0M | 558.0M | 584.0M | 1.84B | 823.0M | 1.44B | 1.16B | 1.31B | 786.0M |
| Total liabilities | 1.97B | 1.64B | 1.56B | 1.47B | 2.95B | 1.79B | 2.55B | 2.38B | 2.35B | 1.22B |
| Shareholders' equity | 6.25B | 6.04B | 5.59B | 5.39B | 4.26B | 3.95B | 2.37B | 2.18B | 1.88B | 1.28B |
| Shares outstanding | 265.1M | 267.0M | 267.0M | 260.7M | 254.4M | 253.2M | 248.0M | 247.5M | 247.7M | 243.0M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1.06B | 791.0M | 813.0M | 518.0M | 95.0M | 328.0M | 295.0M | 533.0M | 554.0M | 462.0M |
| Capital spending | -578.0M | -117.0M | -88.0M | -326.0M | -558.0M | -584.0M | -430.0M | -261.0M | -2.00M | -159.0M |
| Free cash flow | 487.0M | 674.0M | 725.0M | 192.0M | -463.0M | -256.0M | -135.0M | 272.0M | 552.0M | 303.0M |
| Cash from investing | -767.0M | -384.0M | -289.0M | -326.0M | -558.0M | -874.0M | -430.0M | -261.0M | -1.16B | -141.0M |
| Cash from financing | -632.0M | -153.0M | -65.0M | -222.0M | 586.0M | 512.0M | 114.0M | -216.0M | 651.0M | -323.0M |
| Dividends paid | -110.0M | -102.0M | 0 | -74.0M | -72.0M | -94.0M | -98.0M | -92.0M | -75.0M | |
| Share buybacks | -450.0M | 0 | 0 | -493.0M | 0 | |||||
| Change in cash | -330.0M | 254.0M | 459.0M | -30.0M | 123.0M | -34.0M | -22.0M | 57.0M | 44.0M | -2.00M |
Cap table
Built by 6ix from Ambu A/S Class B’s releases
- Common shares
- 226,332,702
- Fully diluted
- 226,332,702
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 226,332,702 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 226,332,702 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Britt Meelby Jensen | Chief Executive Officer · Since at least Nov 5, 2026 |
| Finn Möhring | Chief Technology Officer, R&D · Since at least Nov 5, 2026 |
| Graziela Malucelli | Chief Operations Officer · Since at least Nov 5, 2026 |
| Henrik Skak Bender | Chief Financial Officer · Since at least Nov 5, 2026 |
| Jesper Johnsen Steen | Chief Marketing Officer · Since at least Nov 5, 2026 |
| Scott Heinzelman | President of Ambu North America · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Ambu A/S.